# ImmunogenX

ImmunogenX is an Asset Manager based in Newport Beach, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Newport Beach, United States
- **Region:** North America
- **Address:** Newport Beach, CA, United States
- **Assets under management:** Undisclosed
- **Website:** immunogenx.com

## Regulatory record

- **Reports private funds:** No

## About

ImmunogenX is a clinical-stage biotechnology company founded in 2013 in Newport Beach, California. It develops therapeutic solutions for celiac disease, offering investigational medications and clinical research trials. ImmunogenX was acquired by First Wave Bio in March 2024.

## Sectors

- Digital Health

## Questions

### What is the status of ImmunogenX's lead candidate, latiglutenase?

Latiglutenase is an orally administered enzyme therapy that has completed multiple Phase 2 clinical trials, most notably the CeliAction study which enrolled over 600 patients with celiac disease. The candidate is designed to be an adjunct to a gluten-free diet for patients who continue to experience symptoms. No Phase 3 initiation date has been publicly disclosed.

### How does latiglutenase's mechanism differ from other celiac disease therapies in development?

Latiglutenase degrades gluten in the stomach and proximal small intestine before it can trigger an immune response in the duodenum, using two recombinant gluten-specific proteases. Most other celiac disease candidates target downstream immune pathways — such as IL-15 inhibitors, transglutaminase 2 inhibitors, or tolerance-induction vaccines — rather than eliminating the antigen itself. This places the therapy in a unique mechanistic category.

### What regulatory pathway is ImmunogenX pursuing for latiglutenase?

The firm has engaged with the FDA on clinical endpoints for celiac disease trials, participating in the evolving discussion around patient-reported outcomes and histologic improvement as co-primary endpoints. A formal registrational pathway has not been publicly announced, but the CeliAction data has informed ongoing dialogue around what constitutes a clinically meaningful benefit in this population.

### Who is backing ImmunogenX financially?

ImmunogenX has not publicly disclosed its investor syndicate, nor has it announced venture rounds by name or amount. Public records do not identify named principals or board members. The absence of this information is typical for early- to mid-stage biotech firms that have not yet entered a public registration process.

### Is ImmunogenX publicly traded?

No. ImmunogenX has not filed for an initial public offering, and no ticker symbol or public listing is associated with the firm as of mid-2026. The firm operates privately.

## Related profiles

- [HC Technologies](https://altss.com/profile/hc-technologies)
- [Chmod Ventures](https://altss.com/profile/chmod-ventures)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/immunogenx

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology